Northrop Grumman Receives Milestone C Approval for Joint Counter Radio-Controlled Improvised Explosive Device Electronic Warfare System

Northrop Grumman Corporation has received Milestone C approval for its Joint Counter Radio-Controlled Improvised Explosive Device Electronic Warfare (JCREW) Increment 1 Build 1 (I1B1) system from the U.S. Naval Sea Systems Command (NAVSEA).

The JCREW I1B1 system is a jammer that defeats devices used to trigger improvised explosive devices (IEDs). Northrop Grumman developed mounted, dismounted and fixed-site variants to protect warfighters, vehicles and permanent structures.

"Northrop Grumman appreciates and applauds the contributions of every member of the JCREW team that are enabling this critical capability to be deployed next year to protect our warfighters against current and emerging threats," said Jeannie Hilger, vice president and general manager, Communications division, Northrop Grumman Information Systems. "We've developed a system that's exceedingly more effective against a multitude of different IED threats than currently fielded systems. Northrop Grumman has also added capabilities to JCREW I1B1 that aren't available today that make the system easier to maintain and enable quick updates to jamming profiles."

Prior to achieving Milestone C, the JCREW I1B1 system successfully completed developmental testing, a functional configuration audit, and system verification review.

The developmental test process consisted of a series of tests at five different sites that demonstrated and verified key requirements. These included verifying system protection distance performance in realistic electromagnetic environments (Yuma Proving Ground, Arizona); establishing radio frequency compatibility with other U.S. government communications and jamming equipment (Dahlgren, Virginia); ensuring soldiers using the system were safe and protected from electromagnetic radiation, hazardous transmission levels to ordnance, and hazardous power levels to fuels in close proximity (San Antonio); testing the network features of the JCREW I1B1 jammers (Indian Head, Maryland); and demonstrating the reliability of multiple systems in an open-air environment (Lake Glendora, Indiana). The functional configuration audit confirmed the three system variants met all requirements.

NAVSEA awarded Northrop Grumman a contract option in January 2013 to complete development of JCREW I1B1. NAVSEA previously awarded the company a JCREW development contract with options in December 2009.

Northrop Grumman is a leading global security company providing innovative systems, products and solutions in unmanned systems, cybersecurity, C4ISR, and logistics and modernization to government and commercial customers worldwide. Please visit www.northropgrumman.com for more information.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Northrop Grumman Corporation. (2019, February 24). Northrop Grumman Receives Milestone C Approval for Joint Counter Radio-Controlled Improvised Explosive Device Electronic Warfare System. AZoSensors. Retrieved on November 24, 2024 from https://www.azosensors.com/news.aspx?newsID=8671.

  • MLA

    Northrop Grumman Corporation. "Northrop Grumman Receives Milestone C Approval for Joint Counter Radio-Controlled Improvised Explosive Device Electronic Warfare System". AZoSensors. 24 November 2024. <https://www.azosensors.com/news.aspx?newsID=8671>.

  • Chicago

    Northrop Grumman Corporation. "Northrop Grumman Receives Milestone C Approval for Joint Counter Radio-Controlled Improvised Explosive Device Electronic Warfare System". AZoSensors. https://www.azosensors.com/news.aspx?newsID=8671. (accessed November 24, 2024).

  • Harvard

    Northrop Grumman Corporation. 2019. Northrop Grumman Receives Milestone C Approval for Joint Counter Radio-Controlled Improvised Explosive Device Electronic Warfare System. AZoSensors, viewed 24 November 2024, https://www.azosensors.com/news.aspx?newsID=8671.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.